EKF Diagnostics Holdings plc is a diagnostics & research business based in the UK. EKF Diagnostics Holdings shares (EKF.LSE) are listed on the London Stock Exchange (LSE) and all prices are listed in pence sterling. Its last market close was 64p – an increase of 1.59% over the previous week. EKF Diagnostics Holdings employs 309 staff and has a trailing 12-month revenue of around £49.8 million.
Since the stock market crash in March caused by coronavirus, EKF Diagnostics Holdings's share price has had significant positive movement.
Its last market close was 64p, which is 44.53% up on its pre-crash value of 35.5p and 286.02% up on the lowest point reached during the March crash when the shares fell as low as 16.5794p.
If you had bought £1,000 worth of EKF Diagnostics Holdings shares at the start of February 2020, those shares would have been worth £604.90 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £1,960.19.
|Latest market close||64p|
|52-week range||16.3523p - 81.8754p|
|50-day moving average||63.8382p|
|200-day moving average||56.8197p|
|Wall St. target price||30p|
|Dividend yield||0.01p (1.57%)|
|Earnings per share (TTM)||1.4p|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2021-01-14)||-14.67%|
|1 month (2020-12-22)||-3.03%|
|3 months (2020-10-22)||64|
|6 months (2020-07-21)||42.22%|
|1 year (2020-01-21)||88.96%|
|2 years (2019-01-21)||99.69%|
|3 years (2018-01-19)||208.01%|
|5 years (2016-01-21)||769.27%|
Valuing EKF Diagnostics Holdings stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of EKF Diagnostics Holdings's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
EKF Diagnostics Holdings's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 45x. In other words, EKF Diagnostics Holdings shares trade at around 45x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the FTSE 250 at the end of September 2019 (19.71). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
EKF Diagnostics Holdings's EBITDA (earnings before interest, taxes, depreciation and amortisation) is £13.2 million.
The EBITDA is a measure of a EKF Diagnostics Holdings's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||£49.8 million|
|Operating margin TTM||19.16%|
|Gross profit TTM||£23.7 million|
|Return on assets TTM||6.28%|
|Return on equity TTM||9.1%|
|Market capitalisation||£288.9 million|
TTM: trailing 12 months
Dividend payout ratio: 5000% of net profits
Recently EKF Diagnostics Holdings has paid out, on average, around 5000% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.57% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), EKF Diagnostics Holdings shareholders could enjoy a 1.57% return on their shares, in the form of dividend payments. In EKF Diagnostics Holdings's case, that would currently equate to about 0.01p per share.
EKF Diagnostics Holdings's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
The latest dividend was paid out to all shareholders who bought their shares by 5 November 2020 (the "ex-dividend date").
Over the last 12 months, EKF Diagnostics Holdings's shares have ranged in value from as little as 16.3523p up to 81.8754p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while EKF Diagnostics Holdings's is 0.8274. This would suggest that EKF Diagnostics Holdings's shares are less volatile than average (for this exchange).
EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, and Africa. It offers DiaSpect and DiaSpect T hemoglobin analyzers; DiaSpect Hemoglobin T Low to determine low levels of hemoglobin in plasma and serum specimens, aqueous solutions, or stored or banked erythrocytes; Hemo Control, a point-of-care hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes in a point-of-care setting; and STAT-Site M Beta-hydroxybutyrate analyzer. In addition, it offers Creamatocrit Plus, an analyzer for detecting the lipid concentration and calorific density in mothers' milk; QuPID and True20 pregnancy tests; and Lactate Scout 4, a lactate analyzer. Further, the company offers Altair 240, a chemistry analyzer; Excel, a semi-automated chemistry analyzer; Micro 12, a micro centrifuge for clinical, molecular, and bacteriological applications; sTNFRr1, a predictive marker of end stage renal disease; Hema-Screen Serology, an analyzer dependent for early detection of colorectal cancer; Uri-Trak 120 urine analyzer; and RaPET Serology immunoassay kits, as well as reagents, calibrators, standards, and controls. Additionally, it provides contract manufacturing services, as well as services and distributes third party company's products. It sells its products directly to hospitals, laboratories, and government agencies, as well as through a network of distributors. EKF Diagnostics Holdings plc was founded in 1990 and is headquartered in Cardiff, the United Kingdom.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.